Cargando…

The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma

Millions of people worldwide are affected by traumatic spinal cord injury, which usually results in permanent sensorimotor disability. Damage to the spinal cord leads to a series of detrimental events including ischaemia, haemorrhage and neuroinflammation, which over time result in further neural ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Guijarro-Belmar, Alba, Domanski, Dominik Mateusz, Bo, Xuenong, Shewan, Derryck, Huang, Wenlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996029/
https://www.ncbi.nlm.nih.gov/pubmed/32985466
http://dx.doi.org/10.4103/1673-5374.293256
_version_ 1783670030029815808
author Guijarro-Belmar, Alba
Domanski, Dominik Mateusz
Bo, Xuenong
Shewan, Derryck
Huang, Wenlong
author_facet Guijarro-Belmar, Alba
Domanski, Dominik Mateusz
Bo, Xuenong
Shewan, Derryck
Huang, Wenlong
author_sort Guijarro-Belmar, Alba
collection PubMed
description Millions of people worldwide are affected by traumatic spinal cord injury, which usually results in permanent sensorimotor disability. Damage to the spinal cord leads to a series of detrimental events including ischaemia, haemorrhage and neuroinflammation, which over time result in further neural tissue loss. Eventually, at chronic stages of traumatic spinal cord injury, the formation of a glial scar, cystic cavitation and the presence of numerous inhibitory molecules act as physical and chemical barriers to axonal regrowth. This is further hindered by a lack of intrinsic regrowth ability of adult neurons in the central nervous system. The intracellular signalling molecule, cyclic adenosine 3′,5′-monophosphate (cAMP), is known to play many important roles in the central nervous system, and elevating its levels as shown to improve axonal regeneration outcomes following traumatic spinal cord injury in animal models. However, therapies directly targeting cAMP have not found their way into the clinic, as cAMP is ubiquitously present in all cell types and its manipulation may have additional deleterious effects. A downstream effector of cAMP, exchange protein directly activated by cAMP 2 (Epac2), is mainly expressed in the adult central nervous system, and its activation has been shown to mediate the positive effects of cAMP on axonal guidance and regeneration. Recently, using ex vivo modelling of traumatic spinal cord injury, Epac2 activation was found to profoundly modulate the post-lesion environment, such as decreasing the activation of astrocytes and microglia. Pilot data with Epac2 activation also suggested functional improvement assessed by in vivo models of traumatic spinal cord injury. Therefore, targeting Epac2 in traumatic spinal cord injury could represent a novel strategy in traumatic spinal cord injury repair, and future work is needed to fully establish its therapeutic potential.
format Online
Article
Text
id pubmed-7996029
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-79960292021-06-02 The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma Guijarro-Belmar, Alba Domanski, Dominik Mateusz Bo, Xuenong Shewan, Derryck Huang, Wenlong Neural Regen Res Review Millions of people worldwide are affected by traumatic spinal cord injury, which usually results in permanent sensorimotor disability. Damage to the spinal cord leads to a series of detrimental events including ischaemia, haemorrhage and neuroinflammation, which over time result in further neural tissue loss. Eventually, at chronic stages of traumatic spinal cord injury, the formation of a glial scar, cystic cavitation and the presence of numerous inhibitory molecules act as physical and chemical barriers to axonal regrowth. This is further hindered by a lack of intrinsic regrowth ability of adult neurons in the central nervous system. The intracellular signalling molecule, cyclic adenosine 3′,5′-monophosphate (cAMP), is known to play many important roles in the central nervous system, and elevating its levels as shown to improve axonal regeneration outcomes following traumatic spinal cord injury in animal models. However, therapies directly targeting cAMP have not found their way into the clinic, as cAMP is ubiquitously present in all cell types and its manipulation may have additional deleterious effects. A downstream effector of cAMP, exchange protein directly activated by cAMP 2 (Epac2), is mainly expressed in the adult central nervous system, and its activation has been shown to mediate the positive effects of cAMP on axonal guidance and regeneration. Recently, using ex vivo modelling of traumatic spinal cord injury, Epac2 activation was found to profoundly modulate the post-lesion environment, such as decreasing the activation of astrocytes and microglia. Pilot data with Epac2 activation also suggested functional improvement assessed by in vivo models of traumatic spinal cord injury. Therefore, targeting Epac2 in traumatic spinal cord injury could represent a novel strategy in traumatic spinal cord injury repair, and future work is needed to fully establish its therapeutic potential. Wolters Kluwer - Medknow 2020-09-22 /pmc/articles/PMC7996029/ /pubmed/32985466 http://dx.doi.org/10.4103/1673-5374.293256 Text en Copyright: © 2021 Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review
Guijarro-Belmar, Alba
Domanski, Dominik Mateusz
Bo, Xuenong
Shewan, Derryck
Huang, Wenlong
The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma
title The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma
title_full The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma
title_fullStr The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma
title_full_unstemmed The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma
title_short The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system trauma
title_sort therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (epac) for central nervous system trauma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996029/
https://www.ncbi.nlm.nih.gov/pubmed/32985466
http://dx.doi.org/10.4103/1673-5374.293256
work_keys_str_mv AT guijarrobelmaralba thetherapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT domanskidominikmateusz thetherapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT boxuenong thetherapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT shewanderryck thetherapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT huangwenlong thetherapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT guijarrobelmaralba therapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT domanskidominikmateusz therapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT boxuenong therapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT shewanderryck therapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma
AT huangwenlong therapeuticpotentialoftargetingexchangeproteindirectlyactivatedbycyclicadenosine35monophosphateepacforcentralnervoussystemtrauma